SomnoMed (SOM) AGM 2025 Presentation summary

Financial performance and growth

• Achieved revenue of $111.5 million in FY25, up 22% year-over-year and above guidance.

• EBITDA reached $9.2 million, a significant turnaround with margin improving from 1% to 8%.

• Positive operating and free cash flow, with a cash balance of $17.3 million at June 30, 2025.

• FY26 guidance reaffirmed: revenue $119–$126 million, EBITDA $10–$12 million, capex $6–$8 million.

Operational improvements and leadership

• Manufacturing capacity increased by over 50% from previous constraints, eliminating backlogs.

• Turnaround times for customers significantly improved across all regions.

• Key leadership hires in manufacturing, product, finance, people, and quality strengthened execution.

• Board and management refreshed, adding sector and supply-chain expertise.

Strategic initiatives and innovation

• Rest Assure® received FDA clearance as the first oral device with built-in compliance monitoring.

• US clinical study for Rest Assure® efficacy to commence in FY26, with Clayton Sleep Institute as a site.

• Ongoing investment in operational efficiency, manufacturing expansion, and R&D pipeline.

• Focus on making oral appliance therapy a mainstream treatment for sleep apnea.